CroatiaJGL Group, a Croatian pharmaceutical company, reported significant financial growth in the first half of the year, with total revenue reaching €177.6 million, representing a 13.8% increase compared to the same period last year. The company’s EBITDA rose by 21.6% to €38.3 million, with a margin of 22.6%. Consolidated pre-tax profit increased by 15.8% to €34.8 million. Over the past 12 months, EBITDA reached €67.2 million, indicating strong investment potential. The company plans to invest heavily in production capacity, technology, quality, and R&D through its 'NEBO' project, aiming to expand key brands and enter new international markets. Leading brands like Aknekutan, Aqua Maris, and Vizola S saw double-digit sales growth. Additionally, JGL expanded its product portfolio by launching 27 new products and implemented a major pay raise cycle and organizational restructuring.
Bias read (Center): The article focuses on the financial performance of a private pharmaceutical company, detailing revenue, profit margins, and investment plans. There is no mention of political figures, policies, or contentious issues. The content is purely economic and does not exhibit any ideological framing or slm
